ONCN Stock Chart & Stats
$2530.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2530.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,530.00 - $2,530.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$658.90B
Enterprise Value$29.79K
Total Cash (Recent Filing)$5.10B
Total Debt (Recent Filing)$1.14B
Price to Earnings (P/E)24.7
Beta0.00
Next Earnings
Nov 05, 2026EPS Estimate
32.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)76.57
Shares Outstanding109,786,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7,099.55Price Target Upside180.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)123.49
Revenue Forecast (FY)$114.60B
Bulls Say, Bears Say
Bulls Say
BRUKINSA Market LeadershipBRUKINSA's leading position, broad indication coverage, and presence across 80+ markets create a scalable commercial base. Treatment of more than 300,000 patients supports recurring demand and provides infrastructure for further geographic and label expansion.
Strong Profitability And Cash GenerationThe recent profitability inflection and substantial free cash flow improve BeOne's ability to fund clinical development, manufacturing expansion, and commercialization internally. High gross margins and improving cash conversion also strengthen resilience as the portfolio expands.
Expanding Oncology PipelineRegulatory progress and several late-stage programs broaden BeOne beyond its current lead product. A deeper pipeline can support additional indications, reduce reliance on one franchise over time, and create new commercial opportunities in hematology and solid tumors.
Bears Say
Intensifying Competitive PressureCompetition in BTK and combination therapies could raise promotional requirements, constrain pricing, or slow BRUKINSA share gains. Even without meaningful current U.S. impact, rival launches may pressure adoption and economics as treatment options broaden.
Historical Cash Flow Volatility And Higher LeverageCurrent liquidity and cash generation are strong, but the recent turnaround follows multiple years of losses and negative cash flow. Higher leverage than earlier periods increases the importance of sustained earnings and disciplined investment if operating conditions weaken.
Pipeline And Margin Execution RiskThe mixed CELESTIAL-301 result creates uncertainty around one combination program's differentiation and regulatory reception. At the same time, higher spending on commercial and pipeline activities may delay margin expansion if trials or launches fail to generate expected returns.
BeOne Medicines News
ONCN FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $2530.00 and its highest was $2530.00 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $658.90B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Nov 05, 2026 which is in 51 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Aug 05, 2026. The company reported $34.814 earnings per share for the quarter, beating the consensus estimate of $28.208 by $6.606.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 32.28.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,786,920 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $34.814 in its last earnings report, beating expectations of $28.208. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in MX:ONCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7,099.55 (180.61% Upside)
$7,099.55 (180.61% Upside)
Blogger Sentiment
Bullish
MX:ONCN Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $130.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BeOne Medicines
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONCN Company Deck
ONCN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.View all MX:ONCN earnings summariesONCN Stock 12 Month Forecast
Average Price Target
$7,099.55
▲(180.61% Upside)